MX357888B - Sales basicas de adicion de nitroxolina y usos de las mismas. - Google Patents
Sales basicas de adicion de nitroxolina y usos de las mismas.Info
- Publication number
- MX357888B MX357888B MX2015012720A MX2015012720A MX357888B MX 357888 B MX357888 B MX 357888B MX 2015012720 A MX2015012720 A MX 2015012720A MX 2015012720 A MX2015012720 A MX 2015012720A MX 357888 B MX357888 B MX 357888B
- Authority
- MX
- Mexico
- Prior art keywords
- nitroxoline
- addition salts
- base addition
- pharmaceutical compositions
- methods
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
Abstract
Se describen sales basicas de adición novesdosa de nitroxolina con mejorada solubilidad mejorada y secreción incrementada de orina bajo condiciones fisiológicas; se describen también composiciones farmacéuticas y métodos de tratamiento usando las composiciones farmacéuticas; la presente invención se refiere a sales básicas de adición novedosa de nitroxolina que tienen solubilidad y estabilidad mejoradas en soluciones acuosas, en comparación con la nitroxolina u otras sales de nitroxolina; la presente invención se refiere también a composiciones farmacéuticas que comprenden las sales basicas de adición de nitroxolina, y a métodos de tratamiento o de prevención de enfermedades, trastornos y condiciones usando estas composiciones farmacéuticas.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361790059P | 2013-03-15 | 2013-03-15 | |
PCT/US2014/030532 WO2014145723A1 (en) | 2013-03-15 | 2014-03-17 | Base addition salts of nitroxoline and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015012720A MX2015012720A (es) | 2016-06-21 |
MX357888B true MX357888B (es) | 2018-07-27 |
Family
ID=51538074
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015012720A MX357888B (es) | 2013-03-15 | 2014-03-17 | Sales basicas de adicion de nitroxolina y usos de las mismas. |
Country Status (12)
Country | Link |
---|---|
US (1) | US9758484B2 (es) |
EP (1) | EP2970128B1 (es) |
JP (1) | JP6273349B2 (es) |
KR (1) | KR20160021077A (es) |
CN (1) | CN105228984B (es) |
AU (2) | AU2014232722B2 (es) |
BR (1) | BR112015022849B1 (es) |
CA (1) | CA2907338C (es) |
ES (1) | ES2766758T3 (es) |
HK (1) | HK1214589A1 (es) |
MX (1) | MX357888B (es) |
WO (1) | WO2014145723A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3018221C (en) | 2016-03-31 | 2023-03-21 | Asieris Pharmaceutical Technologies Co., Ltd. | Combinational uses of nitroxoline and its analogues with chemotherapies and immunotherapies in the treatment of cancers |
CN112402388A (zh) * | 2019-08-05 | 2021-02-26 | 江苏亚虹医药科技股份有限公司 | 一种用于治疗膀胱癌的口服固体制剂及其制备方法 |
EP4085902A4 (en) * | 2019-12-31 | 2024-01-10 | Jiangsu Yahong Meditech Co Ltd | PHARMACEUTICAL COMPOSITION CONTAINING NITROXOLINE, NITROXOLINE TABLET, METHOD FOR THE PRODUCTION THEREOF AND USE THEREOF |
CN111773193A (zh) * | 2020-07-03 | 2020-10-16 | 江苏亚虹医药科技有限公司 | 含硝羟喹啉赖氨酸盐的药物组合物及其制备方法和用途 |
CN111960998A (zh) * | 2020-08-03 | 2020-11-20 | 江苏亚虹医药科技有限公司 | 硝羟喹啉衍生物及其制备方法和用途 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2745834A (en) * | 1953-02-09 | 1956-05-15 | Phillips Petroleum Co | Stabilization of certain vinyl-pyridines, vinyl quinolines and vinyl-isoquinolines |
US2745832A (en) * | 1954-03-08 | 1956-05-15 | Nuodex Products Co Inc | Metal quinolinolates and methods of making the same |
US3872128A (en) | 1972-03-08 | 1975-03-18 | Union Carbide Corp | Antimicrobial hydroxy quinoline, ethylene-acrylic polymer compositions |
JPS5768831A (en) * | 1980-10-17 | 1982-04-27 | Fuji Photo Film Co Ltd | Heat developable photosensitive material |
JPS57101835A (en) * | 1980-12-17 | 1982-06-24 | Fuji Photo Film Co Ltd | Thermodevelopable photosensitive material |
US4329185A (en) * | 1981-01-21 | 1982-05-11 | Dso "Pharmachim" | Method for the preparation of a biologically active polyamide net |
US5242892A (en) * | 1984-07-27 | 1993-09-07 | The Board Of Trustees Of The University Of Illinois | Chlorophyll biosynthesis modulators |
JPH03284734A (ja) * | 1990-03-31 | 1991-12-16 | Toshiba Corp | 有機非線形光学材料 |
IT1317735B1 (it) | 2000-01-26 | 2003-07-15 | Nicox Sa | Sali di agenti antimicrobici. |
US7511137B2 (en) * | 2003-12-19 | 2009-03-31 | Rigel Pharmaceuticals, Inc. | Stereoisomers and stereoisomeric mixtures of 1-(2,4-pyrimidinediamino)-2-cyclopentanecarboxamide synthetic intermediates |
TWI328006B (en) * | 2003-12-26 | 2010-08-01 | Nissan Chemical Ind Ltd | Crystal form of quinoline compound and process for its production |
US20080207673A1 (en) * | 2005-05-04 | 2008-08-28 | Michel Xilinas | Method for Treating Cancer, Coronary, Inflammatory and Macular Disease, Combining the Modulation of Zinc-and/or Copper Dependent Proteins |
PT2311972E (pt) | 2005-05-11 | 2015-05-13 | Eth Zuerich | Proteínas n-glicosiladas recombinantes de células procarióticas |
EP1892248A1 (en) | 2006-08-21 | 2008-02-27 | Eidgenössische Technische Hochschule Zürich | Specific and high affinity binding proteins comprising modified SH3 domains of FYN kinase |
US8729097B2 (en) | 2008-10-06 | 2014-05-20 | The Johns Hopkins University | Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and SIRT1, and methods of treating disorders |
EP2435036A2 (en) * | 2009-05-28 | 2012-04-04 | Merck Patent GmbH | Ammoniumcarboxylates |
JP2010070557A (ja) * | 2009-12-17 | 2010-04-02 | Anacor Pharmaceuticals Inc | 加水分解抵抗性ホウ素含有治療薬および使用法 |
EP2353599A1 (en) * | 2010-01-28 | 2011-08-10 | University of Ljubljana | 8-hydroxyquinolines as inhibitors of cathepsin B |
DK2730123T3 (da) * | 2011-07-07 | 2020-03-02 | Ericsson Telefon Ab L M | Overleveringsbeslutning i betjenende basisstation baseret på en første og anden type mobilitetsmekanisme |
-
2014
- 2014-03-17 EP EP14762230.2A patent/EP2970128B1/en active Active
- 2014-03-17 KR KR1020157028976A patent/KR20160021077A/ko active Search and Examination
- 2014-03-17 ES ES14762230T patent/ES2766758T3/es active Active
- 2014-03-17 CA CA2907338A patent/CA2907338C/en active Active
- 2014-03-17 CN CN201480025681.5A patent/CN105228984B/zh active Active
- 2014-03-17 BR BR112015022849-6A patent/BR112015022849B1/pt active IP Right Grant
- 2014-03-17 AU AU2014232722A patent/AU2014232722B2/en active Active
- 2014-03-17 MX MX2015012720A patent/MX357888B/es active IP Right Grant
- 2014-03-17 JP JP2016503414A patent/JP6273349B2/ja active Active
- 2014-03-17 WO PCT/US2014/030532 patent/WO2014145723A1/en active Application Filing
- 2014-03-17 US US14/777,185 patent/US9758484B2/en active Active
-
2016
- 2016-03-02 HK HK16102445.9A patent/HK1214589A1/zh unknown
-
2017
- 2017-02-07 AU AU2017200820A patent/AU2017200820A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2016514705A (ja) | 2016-05-23 |
EP2970128B1 (en) | 2019-12-04 |
EP2970128A4 (en) | 2016-11-30 |
AU2014232722A1 (en) | 2015-09-24 |
WO2014145723A1 (en) | 2014-09-18 |
JP6273349B2 (ja) | 2018-01-31 |
ES2766758T3 (es) | 2020-06-15 |
AU2017200820A1 (en) | 2017-03-02 |
AU2014232722B2 (en) | 2017-03-09 |
HK1214589A1 (zh) | 2016-07-29 |
KR20160021077A (ko) | 2016-02-24 |
CA2907338A1 (en) | 2014-09-18 |
CA2907338C (en) | 2019-09-17 |
BR112015022849A2 (pt) | 2017-12-26 |
EP2970128A1 (en) | 2016-01-20 |
CN105228984A (zh) | 2016-01-06 |
CN105228984B (zh) | 2018-03-23 |
US20160031819A1 (en) | 2016-02-04 |
US9758484B2 (en) | 2017-09-12 |
MX2015012720A (es) | 2016-06-21 |
BR112015022849B1 (pt) | 2020-02-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2018236800B2 (en) | DNA-PK inhibitors | |
PH12017501956A1 (en) | Compositions of obeticholic acid and methods of use | |
MX2021007268A (es) | Formas solidas de acido {[5-(3-clorofenil)-3-hidroxipiridin-2-carb onil]amino}acetico, composiciones, y usos de las mismas. | |
IN2015DN01156A (es) | ||
SG10201909545XA (en) | Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof | |
MD4800B1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
MX2016002544A (es) | Compuestos utiles como inmunomoduladores. | |
IN2014DN09434A (es) | ||
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
MX363457B (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
MY181602A (en) | Isochromene derivatives as phosphoinositide 3-kinases inhibitors | |
PH12018500315A1 (en) | Fumagillol heterocyclic compounds and methods of making and using same | |
EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
NZ719169A (en) | Heteroaryl butanoic acid derivatives as lta4h inhibitors | |
MD20170011A2 (ro) | Compuşi imidazopiridazinici | |
CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
WO2016029136A8 (en) | 3-amidobenzamides and uses thereof for increasing cellular levels of a3g | |
MX357888B (es) | Sales basicas de adicion de nitroxolina y usos de las mismas. | |
MX2013002208A (es) | Derivados de sulfonilpiperazina que interactuan con la proteina reguladora de glucocinasa para el tratamiento de diabetes. | |
EA201591704A1 (ru) | Новые устойчивые соли пентадекапептида, способ их получения, их применение в производстве фармацевтических составов и их применение в терапии | |
WO2019040105A3 (en) | COMPOUNDS, SALTS THEREOF AND METHODS FOR THE TREATMENT OF DISEASES | |
MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |